In a xenograft mouse model established from a 5-FU-resistant rectal cancer patient, combined treatment with 5-FU and a CD147 inhibitor resulted in significantly greater suppression of tumor growth, cell proliferation, and glycolipid metabolism than 5-FU monotherapy, highlighting CD147’s role in mediating 5-FU resistance in colorectal cancer by orchestrating glycolipid metabolic reprogramming (77). Here, BSG is linked to rectal cancer.